Symbiosis Pharmaceutical Services has further strengthened its North American presence with the appointment of Dr Thomas Scullion as US Business Development Manager.
He will support increased demand for the contract manufacturing organisation's sterile filling services from biotech companies and aid the company’s growing commercial interests and client relationships in the region.
The appointment has been made just weeks after the sterile manufacturing specialist unveiled a significant surge in demand for its services from the US, driven by biotechnology firms looking for small-scale aseptic manufacturing capabilities in the EU to support clinical trials.
Thomas joins the CMO’s commercial team having worked in business development for the world’s largest drug discovery CRO. He has spent the majority of his career working within the life science industry across both the public and private sectors.
Colin MacKay, CEO at Symbiosis Pharmaceutical Services, said: 'North America continues to be the strongest area of growth for our business so it is essential that we have the best expertise and a sufficient resource in place to drive opportunities for commercial development alongside managing existing relationships in this key territory.'